

AKI Workgroup

Patricia Ayoung-Chee, MD Tracy Johns RN

TQIP AKI definition



If patient meets any of the below criteria

- Serum Creatinine 3x baseline (based on age, race and gender)
- •Serum Creatinine ≥ 4.0mg/dl
- Initiation of Renal Replacement Therapy
- •Urine output < 0.3ml/kg/hr for ≥ 24hrs
- •Anuric for ≥ 12hrs

Check if Present on Admission



Using KDIGO guidelines, AKI definition = any of the following

- Increase SCr by ≥ 0.3 mg/dl within 48 hours
- Increase SCr to ≥ 1.5 X baseline, known or presumed to have occurred within prior 7 days

 Urine volume < 0.5 ml/kg/h for 6 hours

Age (years) Black males (mg/dl [μmol/l])		Other males (mg/dl [µmol/l])	Black females (mg/dl [µmol/l])	Other females (mg/dl [µmol/l])		
20-24	1.5 (133)	1.3 (115)	1.2 (106)	1.0 (88)		
25-29	1.5 (133)	1.2 (106)	1.1 (97)	1.0 (88)		
30-39	1.4 (124)	1.2 (106)	1.1 (97)	0.9 (80)		
40-54	1.3 (115)	1.1 (97)	1.0 (88)	0.9 (80)		
55-65	1.3 (115)	1.1 (97)	1.0 (88)	0.8 (71)		
>65	1.2 (106)	1.0 (88)	0.9 (80)	0.8 (71)		

Estimated glomerular filtration rate = 75 (ml/min per 1.73 m²) = 186 × (serum creatinine [S_{C_r}]) - 1.154 × (age) - 0.203 × (0.742 if female) × (1.210 if black) = exp(5.228 - 1.154 × ln [S_{C_r}]) - 0.203 × ln(age) - (0.299 if female) + (0.192 if black).

Estimated baseline creatinine

https://kdigo.org/wp-content/uploads/2016/10/KDIGO-2012-AKI-Guideline-English.pdf

Ensure patients meet criteria



Urine Output documentation

- Improve accurate, up-to-date weight documentation
- Improve accurate <u>urine output</u> documentation
 - Amount and/or number occurrences

Now for the deep dive



From Registry		Manual Chart Review	Calculated Data			
•	Admit Date	Which AKI Criteria Met	 # days: admit → SCr 3x base 			
•	Age, Ethnicity	 Number IV contrast exams → 1st 48hrs (inc IR) 	SCr peak			
•	MOI	 1st four lab values: SCr & CPK 	CPK peak			
•	Activation level	 Dates: SCr 3x base (if applies), SCr & CPK 				
•	LOS: ED & Hosp	peak values				
•	Dispo: ED, OR & Hosp	 Vasopressor Use: 1st & 2nd 24 hrs 				
•	ISS	Total Time in OR				
•	Comorbidities	 Insulin Use (by type): 1st & 2nd 24 hrs 				
•	AKI Diagnosis Date					
•	Hospital Events: VAP, CLABSI,					
	DVT, Sepsis, etc.					

Lessons Learned



Bimodal distribution of time to AKI (early and late)

EARLY

- 1. Under-identifying patients with early signs of AKI

 All ICU patients labs checked q6hrs in 1st 24hrs of admit (BMP, CBC, lactate, CPK)
- 2. Under-resuscitating patients with rhabdomyolysis

Implementation of rhabdomyolysis guideline, including continued/frequency CPK checks and UO target

3. Increased awareness AKI (ICU providers and nursing)

UO documentation, accuracy and real-time

Intervening on oliguria

Increased use of SVV measurements and POCUS to determine adequate resuscitation

Lessons Learned



Bimodal distribution of time to AKI (early and late)

LATE (future work)

1. Implementation of renal protective bundle

KDIGO Clinical Practice Guideline for Acute Kidney Injury, March 2012, section 3 (*Prevention and Treatment of AKI*)

2. Choice of target patient cohort

Clinical setting/level of care Mechanism of injury

Grady AKI data



	Q3 2020	Q4 2020	Q1 2021	Q2 2021	Q3 2021	Q4 2021	Q1 2022	Q2 2022
No of Cases	13	14	15	13	20	12	11	6
No. of Registry Cases			1544	1903	1786	1725	1525	1831
Median Age				41.6	59.5	47.5	67	75
Median ISS	26	25	14	30	22	16.5	17	17
No of pts with ≥ 2 IV contrast w/i 1st 24hrs	8 (62%)	6 (43%)	5 (33.3%)	7 (53.8%)	11 (55%)	6 (50%)	8 (72.7%)	
No of cases MTC to OR	8 (6 ≥ 4hrs)	12 (4 ≥ 4hrs)	6	7	9	5	3	1 (16.7%)
No of pts with rhabdo (CPK > 5000)	8 (62%)	6 (43%)	4 (26.7%)	3 (23.1%)	6 (30%)	4 (33.3%)	1 (9.1%)	1 (16.7%)
No of CRRT/HD	10 (77%)	9 (64%)	7 (46.7%)	9 (69.2%)	11 (55%)	6 (50%)	8 (72.7%)	5 (83.3%)
No of deaths	8 (62%)	8 (57%)	6 (40%)	5 (38.5%)	7 (35%)	7 (58.3%)	8 (72.7%)	5 (83.3%)
Median days to SCr 3x base/Peak SCr			4/10	5/7	7/9	3/5	9/12	12/13.5
Length of Stay, median (dys)			17	14	17.5	12	23	14
Sepsis							3	1
VAP							4	2
CAUTI							1	0
Readmission to ICU								3

Data Collection Sheet







Dr. Katherine Kohler



Goals

- Discussion on current state of opioid use/prescribing models in trauma patients
- Gather existing multimodal guidelines from trauma centers
- Develop a state level guideline to share with all trauma centers



- Multimodal pain management guideline completed
- Received feedback from larger group
- •Key Sections:
- -Multimodal Medication Options
- -Regional Anesthesia
- -Discharge Planning
- -Patient Education
- -Alternative Pain Management



Multimodal Options: Recommend use of a combination of <u>two or more</u> medication classes that are prescribed on a <u>scheduled</u> basis.

- Tylenol
- •1000mg IV q6hrs for 24hrs with pharmacy approval *Then*
- •1000mg PO q6hrs
- •Max 4g in 24hrs

NSAID

- •Toradol (15mg/30mg) IV q6hrs 24hrs vs 5 days (dose specific based on GFR)
 - <u>Or</u>
- •Toradol 10mg PO q6hrs for 5 days
 - Or
- •lbuprofen 600 q6hrs
 - Or
- Naproxen 500mg q12hrs (250mg for Geriatric)



- •Antispasmodic (Caution for sedating effects and cross reactions in conjunction with other medications)
- Methocarbamol 1000mg IV x 24-48hrs

Then/Or

•Methocarbamol 750mg PO q8hr - Adjust dosing for over 65 years to 500 mg four times daily (least sedating of antispasmodics)

<u>Or</u>

- Metaxalone 800mg PO q8hr
- •Flexeril 5mg PO q8hr
- Consider for refractory spasms:
- •Baclofen 5mg PO q8hr* requires taper if it has been given regularly
- •Gabapentinoid (Caution sedating effects in certain individuals and rare depression)
- •Pregabalin 75mg PO q8hr x 48hrs

<u>Then</u>

•Gabapentin 300mg PO q8hr (max 3600mg/24hrs)



Other

•Lidocaine patches 5% up to 3 patches – Must have 12 hours off in each 24-hour period PRN

PRN Opioid Breakthrough Options

- •Oxycodone 5mg PO q4hr PRN
- •Tramadol 100mg PO q6hr (renal/geriatric 50mg q12hr)
- •Dilaudid 0.25 to 0.5 mg IV Q 2 to 4 hours
- •Morphine 2 to 4 mg IV Q 2 to 4 hours * not for patients with renal dysfunction



Regional Anesthesia

- •Discussion as an adjunct to a multimodal regimen
- •Includes a list of injuries and potential block options
- •Recommendations for work in conjunction with an anesthesia team



Discharge Planning

- •recommendations for clear instructions on titration and how to take medications after discharge.
- •prescriptions given based on inpatient regimen.



Patient Education

- Goals of pain management
- •Types of pain and medications specifically targeted to those types
- •Side effects of opioids
- •Suggested discharge patient education information



Alternative Pain Management

- Life Care Specialist
- •CwC.ngo
- Other non medication adjuncts examples
 - cryotherapy
 - mindful meditation
 - breathing techniques
 - quality sleep
 - acupressure



Next Steps

-Final Draft for review and approval




TBI Workgroup Collaborative

Winter GQIP Conference Chateau Elan, February 2023


Collaborative Report Spring 2022



Mortality by Cohort



Morbidity by Cohort





- •TBI identified as a cohort with opportunity for improvement
- Developed a workgroup to address TBI care in GA
- •Contribution from 94% Level I, Level II, adult and pediatric centers in the state
- Multidisciplinary group









Target Identification (GQIP and Center Drilldowns)

MORTALITY

- -Early
- -Withdrawal of care
- MORBIDITY
- -VAP & pressure ulcers
- DISPOSITION
- -High HLOS
- –Low outpatient resources





Deeper Dive: Eli Mlaver MD

- Population analysis
- Outcome drivers
- Vulnerable populations
- Patient progression
- Disposition after TBI in Georgia





Future: Guideline Development

